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• The DNA replication apparatus of ovarian cancers has a DNA synthesis process that is error-promoting.
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Objective. The objective of this study is to determinewhether an altered DNA replication process is responsible
for some of genetic damage observed in ovarian cancer.
Methods. The replication ﬁdelity of the DNA synthetic process was evaluated in both malignant and non-
malignant human ovarian cells. The types of replication errors produced were identiﬁed. In addition, kinetic
analyses of the efﬁciency of ovarian cancer DNA polymerases for misincorporating nucleotides were performed.
Results.We report for the ﬁrst time that ovarian cancer cells harbor an error promoting DNA replication ap-
paratus which contributes to the decrease in DNA synthetic ﬁdelity exhibited by these cells. Our study also
shows that the decrease in DNA replication ﬁdelity was not a result of an increased DNA replication activity.
In addition, it was observed that the higher rate of DNA replication errors does not result in signiﬁcant differences
in the type of DNA replication-errorsmade during the DNA replication process; just the relative abundance. A de-
tailed kinetic analysis of the efﬁciency of misincorporating nucleotides demonstrated that the DNA polymerases
within the ovarian cancer cells exhibited a signiﬁcant propensity for creating purine–pyrimidine nucleotide mis-
matches relative to non-malignant ovarian cells, while being only slightly more efﬁcient at incorrectly pairing a
purine nucleotide with a purine nucleotide.
Conclusions. All together, these data suggest that the systematic analysis of the DNA replication process in
ovarian cancer could uncover information on some of the molecular mechanisms that drive the accumulation
of genetic damage, and probably contribute to the pathogenesis of the disease.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.Introduction
Genetic instability is expressed in cancer in diverse ways [1]. It may
affect DNA replication associated nucleotide proofreading (leading to
base substitutions, deletions, or additions), chromosomal structure
(producing translocations, sequence gains, or losses), or karyotypicarch Institute, 1500 East Duarte
ision of Medical Sciences, USA.
nc. Open access under CC BY-NC-SA licenseintegrity (resulting in aneuploidy). None-the-less, it is very likely that
genetic instability either induces or accelerates the proliferation of cancer
cells by favoring the emergence of variant cells. It has already been shown
that a controlled alteration of genes involved in genome maintenance
promotes or favors carcinogenesis [2,3].
In ovarian tumors there is a strong correlation between high rates of
DNA synthesis and poor over-all prognosis [4–10]. Based on the avail-
able data, it appears that high levels of ovarian cancer cell DNA synthesis
are associated with an increased probability of lymph-node metastases
[11,12]. Increasingly, data have showed that large numbers ofmutations
present in a variety of human malignancies originate from both DNA
synthesis errors and DNA repair deﬁcits [1,13]. The malignant cell phe-
notype appears as the result of a multi-step development process that
is associated with the accumulation of multiple genetic mutations. The.
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the occurrence and development of cancer via amultistage carcinogenic
transformation [1,13]. The observation that there is extensive genetic
damage in ovarian cancer cells has been associated with a higher than
normal rate of DNA synthesis. Therefore, the high rates of DNA synthesis
and extensive genetic damage exhibited by ovarian tumors suggest that
an alteration in theDNA replicationmachinery of these cells could result
in uncontrolled and error-promoting DNA synthesis.
In an effort to elucidate the role of DNA replication in cancer cell
biology, we have isolated and puriﬁed from non-malignant and ma-
lignant human cell lines and tissues an assembly of DNA replication
proteins, collectively termed the DNA synthesome, that have been
shown to execute in vitro DNA replication [14–19]. The mammalian
cell DNA replication complex is an organized structure that is fully
competent to orchestrate, in vitro, the reactions required to efﬁciently
replicate DNA in intact cells using the well known simian virus 40
(SV40) replication system [14,19]. The human cell DNA synthesome has
been extensively puriﬁed using a combination of biochemical steps that
include centrifugation, polyethylene glycol precipitation, Q-Sepharose
column chromatography, velocity sedimentation, and native PAGE. The
DNA synthesome complex has been shown to contain all the essential
proteins necessary to carry out in vitro DNA replication; DNA polymer-
ases (pols) α, δ, and ε, proliferating cell nuclear antigen (PCNA), replica-
tion factor A (RPA), replication factor C (RFC), topoisomerases I and II,
and DNA ligase I [14–19].
In this article is a description of the results of an evaluation of the
DNA synthesome of ovarian cancer cells. We report here for the ﬁrst
time that ovarian cancer cells harbor a mutagenic DNA replication appa-
ratus. We anticipate that further examination of the DNA replication ap-
paratus of ovarian cancer cells is likely to uncover altered protein factors
that play a critical role in the process leading to the accumulation of some
of the genetic damage, and that these altered factors may themselves
become a hallmark of this disease. In addition, since genetic damage
appears to be a cumulative process in ovarian cancer, it stands to reason
that alteration of DNA replication proteins may be an early event in the
development of this cancer. Therefore, the systematic analysis of the
DNA replication process in ovarian cancer could uncover information
on some of themolecularmechanisms that drive the accumulation of ge-
netic damage, and probably contribute to the pathogenesis of the disease.
It is our contention that a better understanding of the pathogenesis of
ovarian cancer, (i.e. by describing key molecular events in the develop-
ment andmaintenance of the disease),may facilitate the discovery of im-
proved strategies for the prevention, detection and treatment of ovarian
carcinoma.
Materials and methods
Primary non-malignant ovarian surface epithelial (serosa) cell cultures
Non-malignant primary ovarian surface epithelial (NOSE-1 and
NOSE-2) cells were prepared from two different individuals. These cells
were cultured from a “lateral slice” taken fromovertly normal ovaries ac-
quired during surgery on non-malignant gynecological patients with no
history of receiving chemotherapy (as described in 20–22). The slice
was cultured in a 60-mmdish, epithelial side down, in a layer ofmedium
to prevent the drying of tissue and to nourish the cells. Themediumwas
MCDB105/M199 (50:50), 15% FBS, rhEGF (1 μg/ml), 200 mM glutamine,
100 mM sodium pyruvate, gentamycin (25 μg/ml), penicillin (10 U/ml),
and streptomycin (10 μg/ml). As cells grewout from the tissue specimen,
the tissue was moved to another site in the dish until the dish was 50%
conﬂuent. At 80–90% conﬂuency, the cells were trypsinized and trans-
ferred to a 100-mm dish and a multiwell slide. The slide was used to
check cells for the co-expression of vimentin and cytokeratin, using im-
munocytochemistry. All cultures were shown to be 100% positive for
both markers. Cell cultures were expanded by passaging 4–5 times be-
fore harvesting cell pellets and freezing the pellets at −80 °C. DNAsynthesome was prepared from the cell pellets made individually from
NOSE-1 and NOSE-2 as described below.
Ovarian cancer cell cultures
Three different cisplatin sensitive ovarian cancer cell lines were used
in the studies. Hey C2 and OVCAR 432 cells were cultured as monolayers
in Minimum Essential Medium (MEM) (GIBCO-BRL) supplemented with
10% fetal bovine serum (FBS), 10 units/ml penicillin and 10 μg/ml strep-
tomycin. 10 μM sodium pyruvate was added to the medium during the
culture of the OVCAR 432 cells. Hey C2 is a papillary cystadenocarcinoma
cell line [23]. OVCAR-432 is an ovarian carcinoma (histological type
unknown) cell line [24]. BG-1 cells were cultured in Dulbecco's Modiﬁed
Eagle's Medium with Ham's supplement F12 (DMEM/F12) (Sigma), 5%
FBS, and 10 mg/ml kanamycin. BG-1 is derived from a poorly differenti-
ated ovarian adenocarcinoma [25]. When cultures had proliferated
approximately 80% conﬂuency, the cells were scraped into cold
phosphate-buffered saline (PBS) solution and collected by centrifugation
at 1000 rpm, 5 min at 4 °C. The cells were re-suspended and washed
three times with PBS, and then pelleted before being stored at−80 °C.
Puriﬁcation scheme for the ovarian cell DNA synthesome from cell cultures
DNA synthesome preparations were prepared from ovarian cell
lines grown in culture as described above. Cells were harvested and
cell pellets were stored at−80 °C until used for synthesome prepara-
tion. For synthesome preparation, the cell pellets were thawed on ice,
homogenized, fractionated and puriﬁcation of the synthesome was
performed in a series of centrifugation steps and resolution through
a Q-Sepharose chromatography column as previously described
[14,19]. The protein concentrations of the synthesome fractions
were measured using the Bradford method. DNA synthesome prepa-
rations were stored in aliquots at −80 °C until used for analyses.
In vitro DNA replication assay
The activity of the DNA synthesome to support SV40 in vitro DNA
replication in the presence of viral large T-antigen was performed as
described previously [14,19]. One unit of DNA replication activity
was designated as the incorporation of 1 pmol of radiolabeled
deoxynucleotide into DNA at 37 °C per time indicated in the text.
DNA replication ﬁdelity assay
The DNA from each in vitro DNA replication reaction was precipi-
tated and subjected to DpnI digestion as described previously [26,27].
The DpnI-digested in vitro replicated DNA was used to transfect the
Escherichia coli host as described previously [26,27]. The transfection
and plating conditions give intense blue color for thewild-type plasmid,
which facilitates the visualization of mutant phenotypes. The mutant
colonies range fromwhite to intermediate (relatively blue) phenotypes.
Synthesome based primer extension assay
Both the 18 nucleotide primer (P), containing a 5′ ﬂuorescence tag,
and each of the 36 nucleotide templates (T) were synthesized by MCR
Inc. (a Midland Certiﬁed Reagent Company). The P/T single stranded
DNA's (ssDNA) were annealed to one another using a ratio of 1 primer
to 1.2 templates by heating the combined primers and templates to
90 °C in freshly deionized water, followed by gradually cooling the mix-
ture to room temperature. T4-phage DNA polymerase was purchased
from US Biochemical Corporation, and used to generate full-length DNA
in control primer extension assays. Ten-microliter reaction mixtures
containing 2 pM primer/template DNA, 20 μg DNA synthesome fraction,
50 mMTris–HCl (pH 7.4), 10 mMMgCl2, 1 mMDTT, 0.5 mg/ml BSA, 10%
glycerol, and different concentrations of deoxynucleotide tri-phosphates
Fig. 1. Error-promotingDNA synthesis levels for DNA synthesomemediatedDNA replication
in malignant and non-malignant ovarian cancer cell extracts. The levels of error-promoting
synthesis obtainedduring in vitroDNA replicationmediatedby theDNAsynthesome isolated
frommalignant andnon-malignant ovarian cell extracts are represented. Theerror frequency
is represented as a ratio of the frequency of synthetic errors made by the malignant cell
synthesome fraction versus that made by the NOSE-1 and NOSE-2 cell derived synthesome
fractions.
Table 1
(A) Rate of DNA synthesis mediated by the DNA synthesome prepared from malignant
and non-malignant ovarian epithelial cells. (B) Frequency of speciﬁc types of replica-
tion errors produced by the DNA synthesome derived from non-malignant and malig-
nant ovarian cells.
(A)
Source of DNA
synthesome
T-antigen dependent in vitro
DNA replication (units)a
Fold T-antigen dependent
in vitro DNA replication
Non-malignant NOSE-1 17.2 0.96
Non-malignant NOSE-2 18.8 1.04
Hey C2 19.2 1.06
BG-1 18.3 1.01
OVCAR-432 16.9 0.94
(B)
Mutation type Malignant cells Non-malignant cells
Mismatch 88.1 87.5
Deletion 5.8 6.2
Insertion 6.1 6.3
All 100.0 100.0
(% of total mutations observed.)
a Units = picomoles nascent DNA synthesized per microgram of DNA synthesome
protein per hour.
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reaction products were resolved by electrophoresis through a 15% poly-
acrylamide gel containing 7 M Urea in Tris–Borate–EDTA
buffer (TBE) after quenching the reaction by adding 5 μl of 99.9%
formamide. The polyacrylamide gel was scanned using a Fujinon im-
ager (LAS-3000IR) and the ﬂuorescence intensity of individual
bands in the gel was quantiﬁed by Fluorescent Image Scanning ana-
lytical software (FMBIO II). The frequency of incorporating the non-
complementary nucleotide (i.e., the frequency of misincorporation
[which is a measure of the ﬁdelity of the reaction giving rise to
the 36 nt gel band]), was determined as the ratio of the ﬂuorescence
intensity of the 36 nt band of DNA containing the misincorporated
nucleotide, to the ﬂuorescence intensity of the 26 nt band of
DNA containing no nucleotide misincorporations. Eq. I: f misin =
I∑(T + 1) / I∑(T − 1) was used to calculate the frequency of
misincorporation, where (I∑(T + 1) = IT +1 + IT + 2 + …… IT + 9,
and I∑(T − 1) = IT + IT − 1 + IT − 2 + …… IT − 8). The frequency of
nucleotide misincorporation was plotted as a function of the concentra-
tion of the non-complementary nucleotide incorporated into the reac-
tion product, which was used to perform a Michaelis–Menten kinetic
analysis of the frequency of nucleotide misincorporation supported by
the DNA synthesome from the ovarian cancer cells. Vmax (maximal ve-
locity) and Km (concentration of substrate at half-maximal activity)
were determined using GraphPad IV (Prism) software. The Efﬁciency
(E) of nucleotide misincorporation was determined as the ratio of
Vmax to Km using Eq. II: Emisin =Vmax / Km [28]. All kinetic values
were statistically analyzed and compared using a statistical method
of the t-test to determine the difference of nucleotide misincorporation
by the ovarian cancer cells and the NOSE cells.
Results
Ovarian cancer cells harbor a mutagenic DNA replication apparatus
To assess the replication ﬁdelity of the synthesome isolated from
malignant andnon-malignant human ovarian cells theDNA synthesome
replication complex was prepared from the malignant ovarian cell lines
Hey C2, BG-1, and OVCAR-432. For the purpose of comparison, two
different non-malignant primary ovarian cell lines (NOSE-1 and -2), pre-
pared from two different individuals were used. The synthesome was
isolated from these cells as described in the Materials and methods sec-
tion. The DNA replication ﬁdelity of these preparations was evaluated
using a forward mutagenesis assay as described in the Materials and
methods section. The resulting data as described in Fig. 1 show that
the synthesome fraction derived fromovarian cancer cells produced sig-
niﬁcantly more nucleotide errors in nascent DNA than did the complex
from non-malignant cells (~2.5 to almost 5.0-fold). These data suggest
that a distinctly error-promoting replication apparatus was a signiﬁcant
characteristic of the malignant human ovarian cells evaluated.
Error-promoting DNA replication of malignant ovarian cells does not
correlate with an increased rate of in vitro DNA synthesis
To validate that the observed increase in the mutation frequency of
the puriﬁedmalignant ovarian cell replication apparatuswas notmerely
due to an increase in the rate of in vitro DNA synthesis, the amount of
nascent DNA formed during the DNA replication assay mediated by
the DNA synthesome derived from malignant and non-malignant ovar-
ian cells was examined. The replication activity of the DNA synthesome
preparations was examined using the in vitro SV40 DNA replication
assay described in theMaterials andmethods section. The incorporation
of ([α32P]-dCMP) into the nascent daughter DNA molecules was mea-
sured and the level of replication activity was expressed as picomole
nascent DNA synthesized per microgram of DNA synthesome protein
per hour [Table 1A]. It was observed that the large T-antigen dependent
replication activity of the malignant ovarian DNA synthesome was notsigniﬁcantly higher than that of the non-malignant ovarian complex
[Table 1A]. These data indicate that the signiﬁcant decrease in DNA rep-
licativeﬁdelity observed for themalignant ovarian cell DNA synthesome
[Fig. 1] was not related to an increased in vitro DNA replication activity
exhibited by the replication complex.
The types of DNA replication errorsmade bymalignant and non-malignant
ovarian cell synthesome
In order to determine the types of mutations prevalent in the nascent
DNA produced by the synthesome of malignant and non-malignant
ovarian cells, the target gene (lacZα) contained in the in vitro DNA rep-
lication product was sequenced as described in [26]. The in vitro repli-
cated plasmid DNA present in mutant (white phenotype) bacterial
transformants produced during the forward mutagenesis assay was
extracted, puriﬁed, and sequenced. To serve as a positive control, plas-
mid DNA isolated from wild-type (dark blue) transformants was puri-
ﬁed, sequenced, and compared to the published sequence of the lacZα
gene (Stratagene). These wildtype lacZα sequences were used to iden-
tify the nucleotide sequence errors within the target gene sequence.
Automated dideoxynucleotide sequencing of the double-stranded lacZα
gene demonstrated that, while the number of mutations present in
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synthesome derived from BG-1, HEY-C2 and OVACAR-432 cells was
greater than those formed by the non-malignant complex derived from
NOSE-1 and NOSE-2 cells [Fig. 1], there was no signiﬁcant difference in
the types of mutations found in the replicated DNA products [Table 1B].
It was also observed that there were neither mutational hot spots, nor
any particular type of mismatch that was found to occur more frequently
than another in the replicated lacZα gene.
Detailed kinetic analyses of the altered replication ﬁdelity and nucleotide
misincorporation in ovarian cancer cells
As a step toward understanding the molecular mechanism(s)
mediating the reduction in DNA synthetic ﬁdelity exhibited by ovarian
cancer cells relative to non-malignant ovarian surface epithelial cells, we
used the method described by Creighton and Goodman [28] to compare
the kinetics of nucleotide incorporation into nascent DNA by DNA
synthesome fractions isolated from these cells. Using DNA synthesome
preparations from two non-malignant ovarian surface epithelial cell
lines (NOSE-1 and -2) and three established ovarian cancer cell lines
(BG-1, Hey C2, OVCAR-432); we quantiﬁed the extent to which non-
complementary nucleotides were incorporated into newly synthesized
DNA, as described in the Materials and methods section. Nascent DNA
produced in a DNA polymerase extension assay used a primed single-
stranded DNA template, [shown in Fig. 2A], and the reaction products
were resolved from one another by polyacrylamide gel electrophoresis
[Materials andmethods]. Lanes 1–3 are the control/reference lanes, iden-
tifying the position of the 3most abundant reaction products. Lane 1 con-
tains only dialyzed synthesome fraction and the 18 nucleotide (nt) long
primed DNA template; 0nly the position of the 18 nt long primer is visi-
ble. The reaction products formed by puriﬁed T4 bacteria phage DNA
polymerase, in the presence of the primedDNA template and the reaction
mixture are shown in lanes 2–3. The reaction mixture contains, either
dATP, as the sole nucleotide triphosphate (lane 2), which supports syn-
thesis of the nascent (26 nt) DNA up to the dCMP in the template strand
(i.e., 26 nt in length), or dATP and dGTP, which support synthesis of the
full-length (36 nt) nascent DNA (lane 3). Both the source of the DNA
synthesome fraction (cell line) and the precise nucleotide concentration
used in a speciﬁc reaction mixture are indicated at the bottom of each
lane of the gel. The extent of the DNA synthetic reaction supported by
each reaction mixture and DNA synthesome fraction was determined by
quantifying the ﬂuorescence intensity of the 26 nt and 36 nt reaction
products (Materials and methods). We reasoned that if the synthesome
fraction supports a high degree of ﬁdelity, as would be expected for the
synthesome isolated from the NOSE cells, the predominant product
formed would be only 26 nt in length with dATP as the sole nucleotide
in the reaction mixture. However, if the ﬁdelity of the synthesome frac-
tion is reduced relative to that of the synthesome fraction from the
NOSE cells, we expect the 36 nt full-length DNA product to accumulate.
This expectation was based upon the requirement that dATP must be
misincorporated into the nascent DNA strand, opposite the dCMP in the
template; prior to continuing to extend the newly synthesized DNA. We
also anticipated that the frequency of misincorporationwould be propor-
tional to the concentration of the dATP.
The data shown in Fig. 2B conﬁrmed our expectations, and demon-
strated that the frequency of misincorporation of dATP into the 36 nt
strand, was directly proportional to the concentration of the nucleotide
triphosphate, and thatmisincorporation of dATP occurredmore frequent-
ly with synthesome from ovarian cancer cells, than from the NOSE cells.
The DNA polymerase activity in the synthesome fraction from BG-1
cells exhibits a higher degree of DNA synthetic ﬁdelity during the elonga-
tion of the primed DNA template than that of the corresponding fractions
from OVCAR-432 and Hey C2 cells. In Fig. 2C, the data indicated that
misincorporation of dATP opposite the dCMP in the primed template
was directly proportional to the concentration of dATP in the reaction
mixture. Interestingly, while the frequency of misincorporation of dATPinto nascent DNA varied considerably between individual cancer cell
lines (Table 2), and increased in direct proportion to the nucleotide con-
centration in the reaction mixture (Fig. 2C); misincorporation of dATP
into newly synthesized DNA by the NOSE cell synthesome fraction was
quite low, and remained essentially constant; regardless of the concentra-
tion of dATP in the reaction mixture (Fig. 2B). These data suggested that
the ﬁdelity with which NOSE cell DNA polymerase incorporated nucleo-
tides into nascent DNA was excellent; while ovarian cancer cell DNA
polymerase forms A–C pairs at a substantially higher frequency than its
non-malignant cell counter-part. This suggested that the speciﬁcity of
the substrate binding site within the DNA polymerases derived from
non-malignant ovarian and ovarian cancer cells might be fundamentally
distinct from one another. To examine this possibility we evaluated the
kinetics of misincorporating dATP into nascent DNA as a function of
dATP concentration for the DNA synthesome fraction derived from both
of the NOSE cell lines and the three ovarian cancer cell lines.
Evaluation of the kinetics of nucleotide misincorporation by ovarian
cancer cells
Using the approach described by Creighton and Goodman [28] for
determining the ﬁdelity of DNA synthesis mediated by puriﬁed DNA
polymerase, our measurement of the frequency of misincorporation
of dATP into nascent DNA by the synthesome fraction from the vari-
ous ovarian cancer and non-malignant ovarian surface epithelial cell
lines enabled us to examine the kinetics of dATP misincorporation
using essentially Michaelis–Menten kinetics. By treating the fre-
quency of misincorporation as a rate and examining this frequency
of misincorporation as a function of the concentration of the nucleo-
tide being misincorporated, we prepared a plot of (1/frequency of
misincorporation) vs. 1/dATP concentration, and determined a Vmax,
and Km for the misincorporation process for the DNA synthesome frac-
tion in the two NOSE cell lines, and each of the three ovarian cancer cell
lines [Fig. 2D]. Table 2 summarizes the results of our kinetic analysis ex-
amining the formation of a non-complementary A–C base pair by the
DNA polymerases in the synthesome fraction from the non-malignant
ovarian and ovarian cancer cell lines. The Vmax for the reaction synthe-
sizing a full-length nascent DNA containing an A–C base pair was ap-
proximately 4.2 ± 0.37 μmol/min for the synthesome fraction from
both of the NOSE cell lines. Similarly the Km for the reaction has an
average value of 92.7 ± 12.7 μM. Our results indicate that the Vmax
for theDNA synthetic reactionmediated by theDNA synthesome fraction
from the ovarian cancer cell lines was 127.4 μmol/min for the BG-1 cells,
120.4 μmol/min for the OVCAR-432 cells and 133.8 μmol/min for the
Hey C2 cells. The Km, for the DNA synthetic reaction mediated by the
DNA synthesome fraction from the ovarian cancer cell lines was
294.1 μmol for the BG-1 cells, 409.3 μM for the OVCAR-432 cells and
407.0 μM for the Hey C2 cells. Our study shows that the average Vmax
(127.2 ± 6.7 μmol/min) for the synthetic reaction carried out by all of
the ovarian cancer cell lines was approximately 30.7 fold higher than
the average Vmax (4.15 ± 0.37 μmol/min) for that of the NOSE cells
(P = 0.0001). The average Km (370.1 ± 65.7 μM) for the DNA synthetic
reaction mediated by the DNA synthesome fraction from the ovarian
cancer cell lines was approximately 3.99 fold higher than the average
Km (92.7 ± 12.7 μM) for that from the NOSE cells (P = 0.0113).
According to Creighton and Goodman [28], the efﬁciency of forming a
non-complementary base pair during elongation of a primed DNA tem-
plate by the DNA synthesome fraction can be determined as the quotient
of Vmax / Km. Our analysis of the efﬁciency for misincorporating dATP
during the DNA synthetic reaction mediated by the non-malignant
ovarian surface epithelial cells and the ovarian cancer cell lines indicated
that the BG-1 cells were almost 4.3 times as likely tomisincorporate an A
across from a C nucleotide than its non-malignant cell counter-part;
while the OVCAR-432 and Hey C2 cells were almost 6.5–7.2 times
more likely to incorporate a non-complementary nucleotide base than
the NOSE cells (P = 0.0231). These data suggest that the nucleotide
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Fig. 2. Kinetic analysis of error-prone DNA synthesis mediated by the ovarian cancer cell DNA replication apparatus. Misincorporation of dATP into nascent DNA across from a tem-
plate dCMP. (A) The nucleotide sequence of the 18 nt primer and 36 nt single stranded DNA template used in the primer extension assay. (B) PAGE analysis of the DNA primer
extension reaction products formed by the DNA synthesome fraction from NOSE-1 (lanes 4–7); BG-1 (lanes 8–11); NOSE-2 (lanes 12–15); Hey C2 (lanes 16–19) and Ovcar-432
(lanes 20–23) cells. T4 phage DNA polymerase was substituted for the synthesome fraction in control reactions. Lane 1 contains only the primer template duplex and buffer.
Lanes 2–3 contain primer template, T4 DNA polymerase, and one or both dNTP's required to fully extend the primed-template DNA duplex. The position of the labeled 18 nt primer,
the 26 nt nascent DNA, and the 36 nt full length nascent DNA is shown to the left of the gel. The DNA synthesome fraction containing exonuclease activity cleaves primed DNA
template to form 1–2 nt reaction products. The concentration of dATP and dCTP present in individual reactions is shown below the gel in panel B. (C–D) Michaelis–Menten kinetic
analysis of the misincorporation frequency for each of the cell lines, as a function of the dATP concentration. The misincorporation frequency was determined by calculating the
ratio of the ﬂuorescent intensity of the 36 nt band relative to that of the 26 nt band. The panel on the left shows the frequency of misincorporation of dATP into the nascent
DNA by each cell line. The panel on the right shows the results of the Michaelis–Menton kinetic analysis. The data from each cell line is denoted as: (■) NOSE-1; (▲) NOSE-2;
(∇) BG-1; (○) Hey C2; (◊) OVCAR-432.
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afﬁnity for the substrate nucleotide triphosphate than its non-malignant
cell counterpart, and as a result can inappropriately pair dATP with a
dCMP with a greater efﬁciency than non-malignant ovarian cell DNA
polymerases.
Ovarian cancer cell DNA polymerase has a lower afﬁnity nucleotide
triphosphate binding site than its NOSE cell counter-part
To test the concept that the substrate nucleotide triphosphate
binding site within the ovarian cancer cell DNA polymerases could
be misincorporating non-complementary nucleotide triphosphatesduring DNA synthesis with a greater efﬁciency than their non-
malignant cell counter-parts, we repeated the kinetic analysis de-
scribed in Fig. 2, using the template shown in Fig. 3A. For this analysis,
we used the 5′ ﬂuorescently labeled 18 nt long single-stranded DNA
primer and another 36 nt long single stranded DNA template contain-
ing a dGMP at position 27 in place of the dCMP within the 36 nt long
DNA template used in the studies described in Fig. 2. The primer and
template were annealed to one another over the ﬁrst 18 nucleotides
of the template as described in the Materials and methods section.
The reaction mixture contained dGTP substituted for the dATP used in
the previous experiment. The synthesome fraction from either the
NOSE cells or the ovarian cancer cell lines were used in the assay.
Table 2
Kinetic analysis of nucleotide misincorporation by NOSE and ovarian cancer cells.
Cell line Mis-incorporation of A–C Mis-incorporation of G–G
Vmax Km E Vmax Km E
μM/min μM ×102 min−1 μM/min μM ×102 min−1
Non-malignant cells
NOSE-1 3.88 101.7 3.81 4.41 83.7 5.26
NOSE-2 4.41 83.7 5.26 5.45 122.0 4.46
Average 4.15 92.7 4.54 4.93 102.9 4.86
SD ±0.37 ±12.7 ±1.03 ±0.74 ±27.1 ±0.57
Malignant cells
BG-1 127.4(30.7*) 294.1(3.2*) 19.3(4.3*) 33.7(6.8*) 276.2(2.7*) 19.1(3.9*)
Hey C2 133.8(32.2*) 407.0(4.4*) 32.8(7.2*) 36.6(7.4*) 272.1(2.6*) 13.4(2.8*)
OVCAR 432 120.4(29.0*) 409.3(4.4*) 29.4(6.5*) 22.5(4.6*) 281.7(2.7*) 18.0(3.7*)
Average 127.2(30.65*) 370.1(3.99*) 27.2(5.98*) 30.9(6.27*) 276.7(2.69*) 16.8(3.46*)
SD ±6.70 ±65.7 ±7.02 ±7.45 ±4.83 ±3.02
P** 0.0001 0.0113 0.0231 0.0185 0.0013 0.0133
The values of Vmax, Km and the Efﬁciency (E = Vmax / Km) of nucleotide misincorporation are derived from the substrate–velocity curve, and are determined using GraphPad
software (Prism). The symbol (*) shows the fold increase which is the ratio of the Vmax, Km and E value in the ovarian cancer cells and the average Vmax, Km and E in the normal
ovarian surface epithelial (NOSE) cells. P** is a conﬁdence interval assigned to the result of the t test used to compare the differences between the kinetic parameters for the
ovarian cancer cells and the NOSE cells.
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control, and the reaction products formed by T4 DNA polymerase are
shown in lanes 2–3 of the gel, Fig. 3B. The primer extension assay in-
cluded either dGTP, as the sole nucleotide triphosphate, or both dGTP
and dCTP. In the presence of only dGTP, the reaction extended the prim-
erDNA to a length of 26 nt,while in the presence of both dGTP anddCTP,
the primer was extended by T4 DNA polymerase to 36 nt. The concen-
tration of dNTP's used in each of the reactions is indicated at the bottom
of Fig. 3B, and quantiﬁcation of the amount of labeled 26 nt and 36 nt
long reaction product formed in the assay was performed as described
[Materials and methods]. Full-length 36 nt reaction product can only
form if a non-complementary G–G base pair is formed during the reac-
tion. Lanes 1–3 serve as the reference lanes for identifying the relative
position of the 18 nt primer, the 26 nt long initial reaction product,
and the full-length 36 nt long reaction product within the polyacryl-
amide gel. The extent of misincorporation by the NOSE cell lines and
the ovarian cancer cell lines is determined by quantifying the ﬂuores-
cence intensity of the 26 nt and the 36 nt bands resolved by the gel.
Each of the primer extension assays was performed at one of 4 concen-
trations of dGTP, in order to monitor the effect substrate concentration
has on the amount of 26 nt and 36 nt product formed by the DNA
synthesome preparations from each of the cell lines examined. As with
the experiment shown in Fig. 2, the DNA synthesome fraction derived
from the NOSE cell lines formed only a very small amount of full-
length product (36 nt in length), with the bulk of the reaction product
being 26 nt in length; while the DNA synthesome fraction from each
of the ovarian cancer cell lines formed substantially more full-length
(36 nt) product than the NOSE cells. Michaelis–Menten kinetic analysis
of the frequency at which dGTPwasmisincorporated into full-length re-
action product (Fig. 3D) resulted in a kinetic proﬁle formisincorporation
that closely resembled that shown for dATPmisincorporation into newly
synthesized DNA by the DNA synthesome from the NOSE and the
ovarian cancer cell lines. Table 2 shows that both the Km and Vmax asso-
ciated with the incorporation of dGTP into the nascent DNA product
being synthesized by the DNA polymerases in the DNA synthesome
preparation derived from the NOSE cells was essentially the same as
that for the reaction described in Fig. 2. Similarly, the kinetic parameters
associated with the synthesis of the full-length reaction product by the
ovarian cancer cell DNA polymerases were 6.27 fold higher for the
Vmax (P = 0.0185), and 2.69 fold higher for the Km (P = 0.0013), than
that from the NOSE cells. The efﬁciency with which a G–G base pair
forms in the full-length nascent DNA during the reaction with the
ovarian cancer cell DNA polymerases was also 3.46 fold higher than
that of the DNA polymerases from the NOSE cells (P = 0.0133). Thesedata are consistent with our earlier observation that the nucleotide tri-
phosphate binding site of the ovarian cancer cell DNA polymerases had
a lower afﬁnity for the nucleotide substrate than its NOSE cell counter-
part. Also the ovarian cancer cell DNA polymerases misincorporated
nucleotide triphosphates more efﬁciently than the NOSE cell DNA poly-
merases; suggesting that the ovarian cancer cell DNA polymerases are
more error-prone than their non-malignant cell counter-parts.
Our observations summarized in Fig. 4 compare the efﬁciency
with which the DNA polymerases from both the NOSE cells and the
ovarian cancer cells create speciﬁc types of nucleotide mismatches.
Both the NOSE-1 and NOSE-2 cell DNA polymerases exhibit a relatively
high degree of ﬁdelity during extension of a primed DNA template as
compared to their cancer cell counterparts, and consequently exhibit a
low efﬁciency for forming inappropriate purine–pyrimidine or purine–
purine base pairs. In contrast, the DNA polymerases isolated from all of
the ovarian cancer cell lines examined exhibit between 2.8 and 7.2
fold more nucleotide mismatches (G–G and A–C) during extension
of a primed DNA template than their non-malignant cell counter-
parts; regardless of whether they were synthesizing a purine–purine
or a purine–pyrimidine base pair. With regard to the efﬁciency of
misincorporating nucleotides, the DNA polymerases from the ovarian
cancer cells were more likely to create purine–pyrimidine nucleotide
mismatches (4.3–7.2 fold higher) than the NOSE cell polymerase,
while being only slightly more efﬁcient (2.8–3.9 fold) at incorrectly
pairing a purine nucleotide with a purine nucleotide.
Discussion
One of the hallmarks of human cancer is somatic mutations [29].
There are also numerous reports describing a wide variety of chromo-
somal alterations in cancer cells [30–32]. Herein we report on the rela-
tive ﬁdelity of DNA synthesis in ovarian cancer, comparing tumor cell
lines to normal ovarian surface epithelial cells (NOSE) grown in primary
culture. Ovarian carcinomas are derived from ovarian surface epithelial
cells and replication of damaged DNA in response to ovulation may be
involved in the etiology of the cancer [33]. Our results reported here
show that the DNA replication apparatus of ovarian cancers exhibits a
propensity for carrying out an error-promoting DNA synthetic relative
process to that of non-malignant ovarian cells.
The observed error-promoting DNA replication process of ovarian
cancer cells appears to be inherent to these cells and not due to simply
an increase in the rate of the synthetic activity of its DNA replication appa-
ratus. The penchant of the ovarian cancer DNA replication apparatus for
generating single nucleotide errors was demonstrated by the observation
A:
B:Misincorporation G-G
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Fig. 3. Kinetic analysis of error-prone DNA synthesis mediated by the ovarian cancer cell DNA replication apparatus. Misincorporation of dGTP into nascent DNA across from a template
dGMP. (A) The nucleotide sequence of the 18 nt primer and 36 nt single stranded DNA template used in the primer extension assay. (B) PAGE analysis of the DNA primer extension re-
action products formedby theNE/S3 fraction fromNOSE-1 (lanes 4–7); BG-1 (lanes 8–11); NOSE-2 (lanes 12–15); Hey C2 (lanes 16–19) andOvcar-432 (lanes 20–23) cells. T4 phageDNA
polymerase was substituted for the NE/S3 fraction in control reactions. Lane 1 contains only the primer template duplex and buffer. Lanes 2–3 contain primer template, T4 DNA polymer-
ase, and one or both dNTP's required to fully extend the primed-template DNA duplex. The position of the labeled 18 nt primer, the 26 nt nascent DNA, and the 36 nt full length nascent
DNA is shown to the left of the gel. TheNE/S3 fraction containing exonuclease activity cleaves primedDNA template to form1–2 nt reaction products. The concentration of dGTP and dCTP
present in individual reactions is shown below the gel in panel B. (C–D)Michaelis–Menten kinetic analysis of themisincorporation frequency for each of the cell lines, as a function of the
dATP concentration. Themisincorporation frequencywas determined by calculation the ratio of the ﬂuorescent intensity of the 36 nt band relative to that of the 26 nt band. The panel on
the left shows the frequency ofmisincorporation of dGTP into the nascentDNAby each cell line. The panel on the right shows the results of theMichaelis–Mentonkinetic analysis. The data
from each cell line is denoted as: (■) NOSE-1; (▲) NOSE-2; (∇) BG-1; (○) Hey C2; (◊) OVCAR-432.
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ases associated with the DNA replication complex from both non-
malignant ovarian surface epithelial cells and ovarian cancer cells create
speciﬁc types of nucleotide mismatches during DNA synthesis. The
“complexed”DNA polymerases derived from the non-malignant primary
ovarian cells displayed a relatively high degree of ﬁdelity during exten-
sion of a primed DNA template, as compared to the DNA polymerase
from cancer cell lines; and consequently exhibit a low efﬁciency for
forming inappropriate purine–pyrimidine or purine–purine base pairs.
In contrast, the replication complex associated DNA polymerases isolatedfrom all of the ovarian cancer cell lines examined exhibitmore nucleotide
mismatches during extension of a primed DNA template than their
non-malignant ovarian cell counterparts, regardless of whether they
were synthesizing a purine–purine or a purine–pyrimidine base pair.
DNA polymerase enzymes are fastidious in their selection of nucleo-
tides during DNA synthesis, taking care that bases added to the growing
DNA strand are correctly paired with their complements on the tem-
plate strand (i.e., A'swith T's, and C'swithG's). However, these enzymes
do make errors. Cells evolved sophisticated processes for ﬁxing most,
but not all, of thesemistakes. Some of themistakes are corrected during
Fig. 4. DNA synthesome mediated nucleotide misincorporation efﬁciency in malignant
and non-malignant ovarian cells. The efﬁciency of incorporating a non-complementary
nucleotide into nascent DNA is determined using the kinetic analysis described in Fig. 2D.
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corrected following replication in a process called mismatch repair. Re-
garding the observations described in this communication we may be
able to distinguish between the error contributions generated in the
ovarian cancer cells made by the replication process itself versus those
potentially produced by a faulty mismatch repair process. The DNA
synthesome is a puriﬁed multiprotein complex free of mismatch repair
proteins. Therefore, the synthesome permits an observation of the rep-
lication process devoid the mismatch repair process. With this in mind,
two possible mechanisms are suggested by the data presented in this
paper for the potential contribution the ovarian cancer cell DNA replica-
tion apparatusmakes to the accumulation of replication errors. The ﬁrst
is that the replicative polymerases in ovarian cancer cells are more
error-prone with a decreased capacity to correctly select a nucleotide
for incorporation into the growing DNA strand. Or second, the polymer-
ase proof-reading process is faulty in ovarian cancer cells permitting
replication errors to accumulate during DNA synthesis. Further studies
are required to differentiate between these two possibilities. None-
the-less, these explanations do not rule out the potential that in intact
ovarian cancer cells there are additional avenues for the accumulation
of increased base misincorporation that could entail insufﬁcient detec-
tion and repair lesions occurring during DNA replication. Indeed there
are published data to support a potential for DNAmismatch repair deﬁ-
ciency as contributory to the pathogenesis of some types of ovarian
tumors [34–36].
The act of cell proliferation is what in essence makes us prone to
developing cancer, and at the center of cell proliferation is the process
of DNA replication. When a normal cell proliferates and in the process
synthesizes new daughter DNA molecules, a low level of replication
errors randomly occurs. However, genetic lesions that occur in proto-
oncogenes, tumor suppressors, and/or mutator genes have a potential
to transform the normal cell to a malignant one. Our data suggest that
once transformation is established the ovarian cancer cell's DNA replica-
tion apparatus has an enhanced propensity for creating DNA synthetic
errors, potentially leading to the accumulation of genetic lesions in
genes that facilitate and drive ovarian cancer progression. An important
question that needs to be pursued in the future would be to better
understand how early in the ovarian cell transformation process does
its DNA replication apparatus exhibit enhanced error propensity. This
would better clarify the role of ovarian cancer cell DNA replication in
disease progression.
Additional studies are needed to determine whether the recent
work indicating that a signiﬁcant number of serous carcinomas arise
from the fallopian tube [37] is linked with the possibility that normaltubal cells display some propensity for error-prone DNA replication
compared to NOSE. However, it should be noted that there are no cur-
rent data to suggest that DNA replication occurs any differently, with
any greater propensity to error in fallopian tubal epithelium, than any
other epithelium in the body. None-the-less, this does require addi-
tional investigation.
A faithful DNA replication process is crucial to promote cell division
and to limit cancer risk through the preservation of genome integrity
[38]. There is a growing body of data that indicates that oncogene-
induced alterations of the DNA replication program triggers replicative
stress and replication-associated DNA damage; which favor the accu-
mulation of genetic alterations in cancer cells [39–42]. It is therefore
likely that key replication proteins and associated repair/recombination
factors limit cancer development by preventing genomic instability
during DNA replication. Previous work has demonstrated that the
synthesome of both breast cancer and neuroblastoma cells has a signif-
icantly decreased DNA synthesis ﬁdelity than that of the multiprotein
complex of corresponding non-malignant cells [27,43] and these data
complement the work described in this report. The data described in
this manuscript represent the ﬁrst direct experimental evidence indi-
cating that the DNA synthetic machinery of ovarian cancer cells is itself
mutagenic. It should also be noted that recent data on theDNA sequenc-
ing of a wide variety of human tumors have demonstrated that cancer
cells contain thousands of mutations. These data support the concept
that cancer cells express what has been termed a “mutator phenotype”
[44]. The data described in this communication suggest that the acqui-
sition of an error promoting DNA replication apparatus could be one
mechanism used in cancer cells to support a mutator phenotype. One
potential advantage an error promoting DNA replication apparatus
could afford a cancer cell is an ability to adapt to a hostile host. The
systematic analysis of the DNA replication process in ovarian cancer
could uncover information on some of the molecular mechanisms that
drive the accumulation of genetic damage, and probably contribute to
the pathogenesis of the disease. This study suggests that a functionally
altered DNA replication apparatus could be a previously unrecognized
hallmark of ovarian cancer. Therefore, a structural and mechanistic
characterization of the ovarian cancer DNA replication apparatus has
the potential to provide insight into the process(es) whereby tumor
cells can override someof the control signals,which regulate replication
ﬁdelity in non-malignant cells and contribute to the emergence of an
error-promoting DNA replication process. It is our contention that by
better understanding the pathogenesis of ovarian cancer, (i.e. by describ-
ing key molecular events in the development and maintenance of the
disease), we may ﬁnd improved strategies for the prevention, detection
and treatment of ovarian carcinoma.
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